ISPOR Panelists: Can the FDA Advisory Committee Process Be Strengthened?

Panelists at the leading health economics and outcomes conference discuss whether the FDA's process for allowing outside experts to weigh in on drug approvals needs changes.

Related Keywords

Tunis ,S26 ,Tunisia ,Atlanta ,Georgia ,United States ,Emory University ,Joseph Daval ,Genevieve Kanter ,David Howard ,Medicare Evidence Development ,Rubix Health ,Society For Health Economics ,University Of Southern California ,Outcomes Research ,Medicare Advisory Committee ,Advisory Committee ,Program On Regulation ,Coverage Advisory Committee ,Harvard University ,Professional Society ,Health Economics ,Chief Counsel ,Image Credit ,Affordable Care Act ,Fda ,Aducanumab ,Aduhelm ,Fda Advisory Committee ,Ispor ,